Pulmatrix, Inc.
http://pulmatrix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pulmatrix, Inc.
Deal Watch: Vanda Gets Competing Offer From Cycle After Unsolicited Future Pak Bid
Plus deals involving GSK/Elsie, Lilly/QurAlis, Gilead/Cartography as well as tech transfer announcements and deals in brief.
Cipla Points To Large GLP-1 India Opportunity Amid Speculation On Lilly Deal
Cipla refers to the transformational potential of GLP-1s in India, a market with 100m-plus diabetics and rising obesity, amid plans for oral semaglutide and speculation on partnering possibilities. A recalibration in the firm’s specialty products thrust is also seen.
Cipla Points To Large GLP-1 India Opportunity Amid Speculation On Lilly Deal
Cipla refers to the transformational potential of GLP-1s in India, a market with 100m-plus diabetics and rising obesity, amid plans for oral semaglutide and speculation on partnering possibilities. A recalibration in the firm’s specialty products thrust is also seen.
Deal Watch: Early 2020 Deal-Making Boom Starts With Third Bayer/Evotec R&D Alliance
The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
- Other Names / Subsidiaries
-
- Pulmatrix Operating Company, Inc.
- Ruthigen, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice